Fosun Pharma Announces 2022 Annual Results: Achieved Steady

Performance Highlights:
During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable... | March 28, 2023

Related Keywords

United States , India , China , Macao , Macau General , Macau , Australia , Hong Kong , Taiwan , Shanghai , Chinese , Fosun Pharma Artesun , Han Li Kang Rituximab , Getz Pharma , Parsabiv Etelcalcetide , Han Si Zhuang Serplulimab , Han Li Kang , Fosun Pharma , Tridem Pharma , Wu Yifang , Han Si Zhuang , National Medical Insurance Drug Catalogue , European Commission , National Reimbursement Drug List , Amgen , Rating Expert Committee , Cipla , Sinopharm Co Ltd , Innovation For Good Health , Performance Highlights , Han Qu You , Chinese Mainland , Shanghai Fosun Pharmaceutical , Stock Code , Reporting Period , Increased Rd Investment , Remarkable Results , Serplulimab Injection , Microsatellite Instability High , Non Small Cell Lung Cancer , Extensive Stage Small Cell Lung Cancer , Small Cell Lung Cancer , Orphan Drug Designation , Rheumatoid Arthritis , Reimbursement Drug , Emergency Use Authorization , Azvudine Tablets , Genuine Biotech , National Medical Products Administration , Hydrochloride Tablets , Bei Wen , Fosun Kite , Continuously Improvement , Global Operation , Apremilast Tablets , Shanghai Henlius , Gland Pharma , Active Practice , Good Health , Innovation Transformation , Integrated Operation , Steady Growth , Looking Statement , Shanghai Fosun Pharmaceutical Group Co , Td Stock Exchange , News , Information , Press Release , Performance , The , Reporting , Revenue , Gas , Bomb , Ith , Growth , F , Pet , Profit , After , Deducting , Xtraordinary , Rain , Dr , Oss 2196 Cne100001m79 ,